The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
PMV Pharmaceuticals, Inc
PMV Pharmaceuticals, Inc
Kivu Bioscience Inc.
Neonc Technologies, Inc.
AstraZeneca
Radiopharm Theranostics, Ltd
MacroGenics
MacroGenics
SystImmune Inc.
SN BioScience
Boundless Bio, Inc.
Radiopharm Theranostics, Ltd
ImmunityBio, Inc.
VM Oncology, LLC
DualityBio Inc.
Incyte Corporation
Janux Therapeutics
Sichuan Baili Pharmaceutical Co., Ltd.
University of Colorado, Denver
Merck Sharp & Dohme LLC
Incyte Corporation
A2 Biotherapeutics Inc.
Incyte Corporation
Telix Pharmaceuticals (Innovations) Pty Limited
Marengo Therapeutics, Inc.
TransThera Sciences (Nanjing), Inc.
Klus Pharma Inc.
Hutchmed
Theratechnologies
Seagen Inc.
AstraZeneca
Sotio Biotech Inc.
Cyteir Therapeutics, Inc.
Carisma Therapeutics Inc
Travera Inc
Salubris Biotherapeutics Inc
Merck Sharp & Dohme LLC
Xencor, Inc.
TransThera Sciences (Nanjing), Inc.
Evopoint Biosciences Inc.
Shanghai Yunying Medical Technology
Eastern Cooperative Oncology Group
Fate Therapeutics
Xencor, Inc.
Jules Bordet Institute
Xencor, Inc.
Incyte Corporation
Genocea Biosciences, Inc.
AbbVie
Bayer
Incyte Corporation